Экспериментальное изучение фармакокинетики и метаболизма оригинального селективного анксиолитика афобазола
Диссертация
Из литературных данных известно, что в катализ реакций сульфоокисления и гидроксилирования производных бензимидазола основной вклад вносят такие изоформы цитохромов, как CYP2C19, CYP3A4, CYP1A1 и CYP2C9. Abelo et al. на примере родственного по химической структуре афобазолу соединения омепразола было показано, что образование гидроксилированной формы омепразола катализируется CYP2C19, тогда как… Читать ещё >
Список литературы
- Агафонов А.А., Пиотровский В. К. Программа M-ind системы параметров фармакокинетики модельно-независимым методом статистических моментов.//Хим.-фарм.журн., 1991, № 10,с. 16−19.
- Александровский Ю.А., Лобастов О. С., Спивак Л. И., Щукин Б. П. Психогении в экстремальных условиях.-//М., 1991.
- Бойко С.С., Бобков Ю. Г., Жердев В. П. Биодоступность бемитила у крыс.// Фармакология и токсикология, -1987,№ 5,с.54−56.
- Бойко С.С., Бобков Ю. Г., Жердев В.П, Дворянинов А. А. Изучение фармакокинетики бемитила в эксперименте у крыс.// Хим.-фарм. журн., -1987,№ 11,с.1288−1291.
- Бойко С.С., Бобков Ю. Г., Доброхотова Т. А. и др. Экспериментальные и клинические данные о способности бемитила проникать через гематоэнцефалический барьер.// Фармакология и токсикология, -1987,№ 3,с.79−81.
- Жердев В.П., Литвин А. А. Роль и организация фармакокинетических исследований.// Клин. фармакокинетика, 2005, № 2, с. 1−3.
- Косолапов В.А., Островский В. А., Спасов А. А. Защитное действие этомерзола в случае острой гипобарической гипоксии и последующей реконвалесценции.// Экспер. и клин, фармакология, -1996,№ 6,с.51−53.
- Кравцова О.Ю. Обоснование применения мексидола для фенотипирования глюкуроноконъюгации у животных и человека)/ Автореф. диссер. к.б.н., М., -2005, С. 26.
- Лакин К.М., Крылов Ю. Ф. Биотрансформация лекарственных веществ. М.: Медицина — 1981 — С. 344.
- Миронова О.П., Зарубина И. В., Шабанов П. Д. Этомерзол как антиоксидантное средство.-// Биомед. химия 2003 — № 5, с.434−442.
- Морозов И.С. Методические рекомендации по применению бемитила в психиатрической практике.-//М., 1987, с. 120.
- Незнамов Г. Г., Сюняков С. А., Чумаков Д. В. и др. Результаты клинического изучения селективного анксиолитика афобазола.// Экспер. и клин, фармакология 2001- № 2, с. 15−19.
- Пожарский А.Ф., Гарновский А. Д., Симонов A.M. Успехи химии имидазола.// Успехи химии, 1966, № 35, с. 261−281.
- Приходько А.З., Асташкин Е. И. Изучение влияния лекарственных препаратов имидазола и бензимидазола на ферментативные активности цитохрома Р-450 печени мышей).// Хим.фарм.журнал-1992-№ 3, С.23−25.
- Сергиенко В.И., Бондарева И. Б. Математическая статистика в клинических исследованиях. М.:ГЭОТАР-МЕД, 2001, — 256 с.
- Середенин С.Б., Бадыштов Б. А., Егоров Д.Ю.// Исследование содержания продуктов перекисного окисления липидов у инбредных мышей с различным типом эмоционально-стрессовой реакции. Бюлл. эксп. фармакол. мед.- 1989.-N7.- С. 46−48.
- Середенин С.Б., Воронина Т. А., Незнамов Г. Г. и др. Фармакогенетическая концепция анксиолитического эффекта.// Вестник РАМН. 1998-№ 11, С.3−9.
- Смирнов А.В. Фармакологические средства повышения работоспособности.// Из-во Военно-медицинской академии им. А. В. Кирова, Ленинград-1984-с. 31−35.
- Смирнова JI.А. Фармакокинетика производных бензимидазола как основа для создания новых лекарственных препаратов и оптимальных схем фармакотерапии./ Диссер. д.б.н., Волгоград, -2004, С. 338.
- Спасов А.А., Иежица И. Н., Бугаева Л. И., Анисимова В. А. Спектр фармакологической активности и токсикологические свойства производных бензимидазола (обзор).// Хим.-фарм. журн., -1999,№ 5,с.6−17.
- Спасов А.А., Черников М. В., Анисимова В. А. и др. Поиск антигистаминных веществ среди имидазо- и триазолобензимидазолов. //Хим.-фарм. журн., -2000,№ 2,с.6−10.
- Abelo A., Andersson Т.В., Bredberg U. et al. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole./ Drug metabolism and disposition, -2000, Vol. 28, № 1, p. 58−64.
- Ali D.N., Chick B.F. The effect of an oil formulation on the systemic availability of oxfendazole./ Int. J. Parasitol., -1992, Vol. 22, № 4, p. 541 543.
- Ali D.N., Hennessy D.R. The effect of feed intake on the rate of flow of digesta and the disposition and activity of oxfendazole in sheep./ Int. J. Parasitol., -1993, Vol. 23, № 4, p. 477−484.
- Alvarez-Bujidos M.L., Ortiz A.I., Negro A. et al. Pharmacokinetics of triclabendazole in rabbits./ Сотр. Biochem. Physiol. C., -1993, Vol. 106, № 3, p. 805−808.
- Andersson Т., Cederberg C., Edvardsson G. et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole./ Clin. Pharmacol. Ther./, — 1990, Vol.47, p.79−85.
- Andersson Т., Holmberg J., Rohss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole./ Br. J. Clin. Pharmacol., -1998, Vol. 45, p. 369−375.
- Andersson Т., Lagerstrom P.O., Miners J.O. et al. High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism./ J. Chromatogr., — 1993 (a), Vol. 619, p. 291−297.
- Andersson Т., Miners J.O., Tassaneeyakul W. et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism./ Br. J. Clin. Pharmacol., — 1993, Vol.36, p.521−530.
- Andersson Т., Miners J.O., Veronese M.E., Birkett D.J. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism./ Br. J. Clin. Pharmacol., — 1994, Vol.37, p.597−604.
- Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole./ Clin. Pharmacol., — 1996, Vol.31, p. 9−28.
- Andersson Т., Regardh C.G., Dahl-Puustinen M.L., Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators./ Ther. Drug Monit., — 1990, Vol.12, p.415−416.
- Backlund M., Weidolf L., Ingelman-Sundberg M. Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells./ Eur. J. Biochem.,-1999, Vol.26 l, p.66−71.
- Backman J.T., Wang J.S., Wen X. et al. Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam./ Clin. Pharmocol. Ther., -1999, Vol. 66, № 4, p. 401−407.
- Baro F., Brugmans J., Heykants J.J.P. Absorption, metabolism and excretion of pimozide in man./ Clin. Ther., -1972, Vol. 63, p. 239−249.
- Barradell L.B., Faulds D., McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders./ Drugs, — 1992, Vol.44, p. 225−250.
- Benet L., Zech K. Pharmacokinetics a relevant factor for the choice of a drug?/ Aliment. Pharmacol. Ther., -1994, Vol. 8, p. 25−32.
- Bliesath H., Huber R., Hartmann M. et al. Pantoprazole does not influence the steady state pharmacokinetics of nifedipine Abstract./ Gastroenterology, — 1994, Vol.106, A55.
- Blohme I., Idstrom J.P., Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients./ Br. J. Clin. Pharmacol., — 1993, Vol.35, p. 156−160.
- Blume H., Donath F., Warnke A., Schuq. B.S. Pharmacokinetic drug interaction profiles of proton pump inhibitors./ Drug Saf., — 2006, Vol.29, p.769−784.
- Borowski P., Deinert J., Schalinski S. et al. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis С and related viruses./ Eur. J. Biochem., 2003, Vol. 270, № 8, p. 1645−1653.
- Briley M., Nutt D.(eds.) Anxiolytics Birkhauser Verlag — 2000.- P.181
- Capece В., Perez В., Castells E. et al. Liquid chromatographic determination of fenbendazole residues in pig tissues after treatment with medicated feed./ J. AOAC Int., -1999, Vol. 82, № 5, p. 1007−1016.
- Caraco Y., Tateishi Т., Wood A.J. Interethnic difference in omeprazole’s inhibition of diazepam metabolism./ Clin. Pharmacol. Ther., — 1995, Vol.58, p.62−72.
- Cashman J. Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P450 monooxygenases./ Drug Metab. Rev., -1998, Vol. 30, p. 675−707.
- Cavanaugh J.H., Winters E.P., Cohen A., Braeckman R. Lack of effect of lansoprazole on steady state warfarin metabolism./ Gastroenterology, — 1991, Vol.100, A 40.
- Cederberg C., Andersson Т., Skanberg I. Omeprazole: pharmacokinetics and metabolism in man./ Skand. J. Gastroenterol., — 1989, Vol.24, p.33−40.
- Chen С., Andrade J.D. Pharmacokinetic model for simultaneous determination of drug levels in drug and tissues./ J. Pharm. Sci., -1976, Vol. 65, № 5, p. 717−724.
- Chiba K., Kobayashi K., Manabe K. et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4^-hydroxylation./ J. Pharmacol. Exp. Ther., — 1993, Vol.266, p. 52−59.
- Corsini A., Bellosta S., Baetta R. New insights into the pharmacodynamic and pharmacokinetic properties of statins./ Pharm. Ther., -1999, Vol. 84, p. 413−428.
- Dareer S.M., Tillery K.F., Rose L.M. et al. Metabolism and disposition of a thiazolobenzimidazole active against human immunodeficiency virus-1./ Drug Metab. Dispos., -1993, Vol. 21, № 2, p. 231−235.
- Davies В., Morris T. Physiological parameters in laboratory animals and humans./ Pharmaceutical Research, 1993, Vol. 10, № 7, p. 1093−1095.
- Dipiro J.T., Blouin R.A., Pruemer J.M., Sprvill W.J. Concepts in clinical pharmacokinetics. Bethesda: American Society of Health-System Pharmacists 1996. — 200 p.
- Domagala F., Ficheux H., Hourin G., Barre J. Pharmacokinetics of tenatoprazole, a newly synthesized proton pump inhibitor, in healthy male caucasian volunteers./ Arzneim. Forsch., — 2006, Vol.56,№ 1, p.33−39.
- Du Souich P., Besner J., Clozel J. et al. Nonlinear kinetics and pharmacologic response to tiabendazole./ J. Clin. Pharmacol. Ther., -2000, Vol. 67, № 3, p. 249−257.
- Evans G. A handbook of bioanalysis and drug metabolism. CRC Press -2004. 390 p.
- Funk H.B., Nathan H.A. Inhibition of growth of microorganisms by benzimidazoles./ Proc. Soc. Exp. Biol. Med., — 1958, Vol.99, p. 394−397.
- Gugler R., Jensen J.C. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro./ Gastroenterology, — 1985, Vol.89, p.1235−1241.
- Gyurik R.J., Chow A.W., Zaber B. et al. Metabolism of albendazole in cattle, sheep, rats and mice./ Drug Metab. Dispos., 1981, Vol.9, p.503−508.
- Hanauer G., Graf U., Meissner T. In vivo cytochrome P450 interactions of the newly developed H+/K (+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96 022) compared to other antiulcer drugs./ Methods Find. Exp. Clin. Pharmacol., — 1991, Vol.13, p.63−67.
- Hartmann M., Bliesath H., Zeck K. et al. Pantoprazole does not influence CYP1A2 activity in man Abstract./ Gastroenterology, — 1995, Vol.108, A109.
- Hennessy D.R., Ali D.N., Tremain S.A. The partition and fate of soluble and digesta particulate associated oxfendazole and its metabolites in the gastrointestinal tract of sheep./ Parasitol., -1994, Vol. 24, № 3, p. 327−333.
- Hennessy D., Prichard R., Steel J. Biliary secretion and enterohepatic recycling of fenbendazole metabolites in sheep./ J. Vet. Pharmacol. Ther., -1993, Vol. 16, p. 132−140.
- Hobrecker F. Uber Peductionsproducte der Nitramidverbindungen./ Ber.Dtsch.Chem.Ges., 1872, № 5, p. 920−924.
- Hongo M., Ohara S., Hirasawa Y. et al. Effect of lansoprazole on intragastric pH: comparison between morning and evening dosing./ Dig. Dis. Sci., 1992, Vol.37, p. 882−890.
- Horst A., Wiltshire H., Bullingham R. Clinical pharmacokinetics of mibefradil./ Clin. Pharmacokinet., -1998, Vol. 35, № 6, p. 405−423.
- Huber R., Kohl В., Sachs G. et al. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole./ Aliment. Pharmacol. Ther., — 1995, Vol.9, p.363−378.
- Janssen P.A.J., Niemegeers C.J.E., Schellekens K.H.L. et al. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug./ Arzneim. Forsch., -1968, Vol. 18, p. 261−279.
- Janssens M.M. Astemizole. A nonsedating antihistamine with fast and sustained activity./ Clin. Rev. Allergy, -1993, Vol. 11, p. 35−63.
- Jung F., Richardson Т.Н., Raucy J.L., Johnson E.F. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low Km diazepam N-demethylases./ Drug Metab. Dispos.,-1997, Vol.25, p.133−139.
- Kaiser H.B. Hl-receptor antagonist treatment of seasonal allergic rhinitis./ Clin. Immunol., -1990, Vol. 86, № 6, p. 1000−1003.
- Kamilli I., Gresser U., Zollner N. Pharmacokinetics and pharmacodynamics of different doses of irtemazole in repeated application./ Z-Rheumatol., -1991, Vol. 50, № l, p. 23−28.
- Karol M.D., Granneman G.R., Alexander K. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography./ J. Chromatogr., — 1995, Vol. 668, p. 182−186.
- Karol M.D., Mukherji D., Cavanaugh J.H. Lack of effect of concomitant multidose lansoprazole on single-dose phenytoin pharmacokinetics in subjects./ Gastroenterology, — 1994, Vol.106, A 103.
- Katsuki H., Nakamura C., Arimori K. et al. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects./ Eur. J. Clin. Pharmacol., — 1997, Vol.52, p. 391−396.
- Kelly Т., Doble P., Dawson M. Chiral analysis of methadone and its major metabolites (EDDP and EMDP) by liquid chromatography mass spectrometry./ J. Chromatogr. В Analyt. Technol. Biomed. Life Sci., — 2005, Vol.814, p. 315−323.
- Knobloch W., Winkelmann G., Rintelen K. Pharmacological action of benzimidazole. I. 1. 2-Mercaptobenzimidazoles// Arch. Pharmaz., 1958, Vol. 291/63, № 3,p.l 13−116.
- Ко J.W., Sukova N., Thacker D. et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P-450 isoforms. / Drug Metab. Dispos., — 1997, Vol.25, p. 853−862.
- Kolars J., Lown K., Schmiedlin-Ren P. et al. CYP3A gene expression in human gut epithelium./ Pharmacogenetics, -1994, Vol. 4, p. 247−259.
- Kromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds./ Digestion, -1995, Vol. 56, № 6, p. 443−454.
- Krosky P.M., Borysko K.Z., Nassiri M.R. et al. Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus./ Antimicrob. Agents Chemother., 2002, Vol. 46, № 2, p. 478−486.
- Kupfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man./ Eur. J. Clin. Pharmacol., — 1984, Vol.26, p. 753−759.
- Levron J., Gillardin J., Sabbah A. Astemizole: its pharmacokinetics and pharmacologic properties./ Allerg. Immunol. Paris, -1990, Vol. 22, № 6, p. 233−241.
- Levy R.H., Thummel K.E., Trager W.F. et al. (eds.). Metabolic drug interactions. Lippincott Williams&Wilkins, 2000. — P.793.
- Li G., Klotz U. Inhibitory effect of omeprazole on the metabolism of midazolam in vitro./ Arzneimittelforschung, — 1990, Vol.40, p. l 105−1107.
- Lind Т., Andersson Т., Skanberg I., Olbe L. Biliary excretion of intravenous 14C. omeprazole in humans./ Clin. Pharmacol. Ther., — 1987, Vol.42, p.504−508.
- Marinac J.S., Balian J.D., Foxworth J.W. et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype./ Clin. Pharmacol. Ther., — 1996, Vol.60, p. 138−144.
- McCreadie R.G., Heykants J J., Chalmers A., Anderson A.M. Plasma pimozide profiles in chronic schizophrenics./ Br. J. Clin. Pharmacol., 1979, Vol. 7, № 5, p. 533−534.
- McNeil Pharmaceutical. Orap (pimozide) tablets hospital formulary information. -Sprin House PA, London, 1984. P. 500.
- Meyer U.A. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. / Yale J. Biol. Med., — 1996, Vol.69, p. 203−209.
- Miller J. The imidazoles as immunosuppressive agents./ Transplant. Proc., -1980, Vol. 12, № 2, p. 300−303.
- Miura M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma./ Yakugaku Zasshi., -2006, Vol. 126, p. 395−402.
- Murray M., Hudson A., Yassa V. Hepatic microsomal metabolism of the anthelmintic benzimidazole fenbendazole: enhanced inhibition of cytochrome P 450 reactions by oxidized metabolites of the drug./ Chem. Res.Toxicol.,-1992, Vol.5,p.60−66.
- Paine M., Shen D., Kunze K. et al. First-pass metabolism of midazolam by the human intestine./ Clin. Pharmacol. Ther., -1996, Vol. 60, p. 14−24.
- Pearce R.E., Rodrigues A.D., Goldstein J.A., Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism./ J. Pharmacol. Exp. Ther., — 1996, Vol.277, p. 805−816.
- Pedini M., Bistocchi G.A., De Meo G. New heterocyclic derivatives of benzimidazole with germicidal activity HPLC detection of S-fluoro^-^-nitro-2*-fuiyl)benzimidazole (F-0-N02) in biological samples./ Farmaco., -1991, Vol. 46, № 3, p. 509−520.
- Physicians Desk Reference. 47th ed. Montvale, NJ: Medical Economics Company, 1997.
- Pichard L., Curi-Pedrosa R., Bonfils C. et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450./ Mol. Pharmacol., — 1995, Vol.47, p. 410−418.
- Pinder R.M., Brogden R.N., Sawyer et al. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy./ Drugs, -1976, Vol. 12, № 1, p. 37−40.
- Plein K., Hots J., Wurzer H. et al. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-esophageal reflux disease./ Eur. J. Gastroenterol. Hepatol., -2000, Vol. 12, № 4, p. 425−432.
- Pue M.A., Laroche J., Meineke I., De Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy mail subjects./ Eur. J. Clin. Pharmacol., -1993, Vol. 44, № 6, p. 575−578.
- Rawden H., Kokwaro G., Ward S., Edwards G. Relative contribution of cytochromes P450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes./ Br. J. Clin. Pharmacol., -2000, Vol. 49, p. 313−322.
- Regardh C.G., Andersson Т., Lagerstrom P.O. et al. The pharmacokinetics of omeprazole in humans: a study of single intravenous and oral doses./ Ther. Drug Monit., — 1990, Vol.12, p. 163−172.
- Regardh C.G. Pharmacokinetics and metabolism of omeprazole in man./ Skand. J. Gastroenterol., — 1986, Vol.21, p.99−104.
- Renberg L., Simonsson R., Hoffmann K.J. Identification of two main urinary metabolites of 14C. omeprazole in humans./ Drug Metab. Dispos.,-1989, Vol.17, p.69−76.
- Rosenzweig P., Thebault J.J., Caplain et al. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative HI antihistamine./ Ann. Allergy, -1992, Vol. 69, № 2, p. 135−139.
- Sellersville P.A. Orap (pimozide) prescribing information./ Lemmon Company London, 1988, P. 120.
- Seredenin S.B. Genetic differences in response to emotional stress and tranquilizers./ Psihofarmakol. Biol. Narkol., — 2003, Vol.3, № 1−2, p. 494−509.
- Simon W.A. Pantoprazole which cytochrome P450 isoenzymes are involved in its biotransformation./ Gut, — 1995, Vol. 37(Suppl 2), A135.
- Simons F.E. Recent advances in HI-receptor antagonist treatment. / Clin. Immunol., -1990, Vol. 86, № 6, p. 995−999.
- Smith D.A., Ackland M.J., Jones B.C. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates./ Drug Discovery Today, -1997, Vol. 2, p. 479−486.
- Souhaili-el Amri, H, Fargetton, X, Benoit E. et al. Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokinetics./ Toxicol. Appl. Pharmacol, — 1988, Vol. 92, p. 141−149.
- Steinijans V. W, Huber R, Hartmann M. et al. Lack of pantoprazole drug interactions in man./ Int. J. Clin. Pharmacol. Ther, — 1994, Vol.32, p.385−399.
- Tateishi T, Graham S. G, Krivoruk Y, Wood A.J. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test./ Br. J. Clin. Pharmacol, — 1995, Vol.40, p.411−412.
- Thummel K, Kunze K, Shen D. Enzyme-catalyzed process of first-pass hepatic and intestinal drug extraction./ Adv. Drug Deliv. Rev, -1997, Vol. 27, p. 99−127.
- Tucker G.T. The interaction of proton pump inhibitors with cytochromes P450. / Aliment. Pharmacol. Ther, — 1994, Vol.8, p. 33−38.1. О №
- Tybring G., Bottiger Y., Widen J., Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects./ Clin Pharmacol Ther.,-1997, Vol.62, № 2, p.129−137.
- VandenBranden M., Ring B.J., Binkley S.N., Wrighton S.A. Interaction of human liver cytochromes P450 in vitro with LY307640: a gastric proton pump inhibitor./ Pharmacogenetics, — 1996, Vol.6, p.81−91.
- Virkel G., Lifschitz A., Sallovitz J. et al. Comparative hepatic and extra hepatic enantioselective sulfoxidation of albendazole and fenbendazole in sheep and cattle./ Drug metabolism and disposition, -2004, Vol. 32, № 5, p. 536−544.
- Wilson B.V., Knudsen T. Pantoprazole. A new acid pump inhibitor against peptic ulcer and reflux esophagitis./ Ugeskr. Laeger., -1996, Vol. 158, № 12, p. 1695−1697.
- Woodward J.K. Pharmacology of antihistamines./ J. Allergy Clin. Immunol., -1990, Vol. 86, № 4, p. 606−612.
- Zimmermann A.E., Katona B.G. Lansoprazole: a comprehensive review. / Pharmacotherapy, — 1997, Vol.17, p. 308−326.